ArticlePharmaceuticals (Basel, Switzerland)2025

Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma.

Yinhua Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.